Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (93)
February 18, 2008
- Maurer's Healthcare Insight (92)
January 21, 2008
- Maurer's Healthcare Insight (91)
December 24, 2007
- Maurer's Healthcare Insight (90)
November 5, 2007
- Maurer's Healthcare Insight (89)
October 8, 2007
- Maurer's Healthcare Insight (88)
August 6, 2007
- Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
- Maurer's Healthcare Insight (86)
May 28, 2007
- Maurer's Healthcare Insight (85)
April 16, 2007
- Maurer's Healthcare Insight (84)
March 26, 2007
- Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
- Maurer's Healthcare Insight (83)
February 19, 2007
- 2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
- Maurer's Healthcare Insight (82)/Questions from the Floor P. Reed Maurer
December 18, 2006
- Maurer's Healthcare Insight (81)
November 20, 2006
- Maurer's Healthcare Insight (80)
October 23, 2006
- Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
- Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
- Maurer's Healthcare Insight (77)
July 24, 2006
- Maurer's Healthcare Insight (76)
June 26, 2006
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…